Treatment of Brain AVMs (TOBAS): study protocol for a pragmatic randomized controlled trial

Tim E Darsaut, Elsa Magro, Jean-Christophe Gentric, André Lima Batista, Chiraz Chaalala, David Roberge, Michel W Bojanowski, Alain Weill, Daniel Roy, Jean Raymond, Tim E Darsaut, Elsa Magro, Jean-Christophe Gentric, André Lima Batista, Chiraz Chaalala, David Roberge, Michel W Bojanowski, Alain Weill, Daniel Roy, Jean Raymond

Abstract

Background: The management of unruptured brain arteriovenous malformation (AVM) patients remains controversial. Furthermore, curative attempts to treat ruptured AVM patients have not been questioned so far, and there is a lack of prospective data on clinical results according to treatment modality. Endovascular treatment is often used aiming to improve the safety or efficacy of surgery or radiation therapy, but benefits have never been documented in a trial. A care trial context is needed to evaluate interventions at the same time they are practised.

Methods/trial design: TOBAS is a pragmatic, prospective, multicenter, randomized, controlled trial and registry which offers a care trial context for brain AVM patients, including surgical resection, radiosurgery or endovascular embolization, alone or combined. The study includes two RCTs and a multimodality prospective registry. The objectives of the proposed study are to assess whether preventive interventions (surgery, embolization, radiation therapy, alone or combined), selected by the local treatment team and performed as locally practiced, randomly allocated and compared with conservative management, in unruptured brain AVM patients eligible for active or conservative management, can improve the proportion of patients having an independent outcome (modified Rankin Scale (mRS) < 3, as assessed by a standardized questionnaire administered by non-masked care personnel) at 10 years. All patients judged ineligible for randomized allocation are to be entered in a multimodal registry. The objective of a nested trial in patients with ruptured or unruptured AVMs to be treated by surgery or radiation therapy, is to assess whether pre-surgical or pre-radiation embolization, randomly allocated and compared with no embolization, can improve the proportion of patients with complete eradication of the AVM, as locally adjudicated, combined with a good clinical outcome (mRS < 3). The study will require up to 2000 patients in approximately 30 centers or more, followed for 10 years. TOBAS is registered at clinicaltrials.gov: NCT02098252 as of 25 March 2014.

Figures

Fig. 1
Fig. 1
Treatment allocation. The figure illustrates the list of questions (a-d) used by the multidisciplinary team to allocate treatments by clinical judgment (a-b) and/or randomization (c-d)

References

    1. Brown RD, Jr, Wiebers DO, Torner JC, O’Fallon WM. Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted Country, Minnesota. J Neurosurg. 1996;85:29–32. doi: 10.3171/jns.1996.85.1.0029.
    1. Ogilvy CS, Stieg PE, Awad I, Brown RD, Jr, Kondziolka D, Rosenwasser R, et al. AHA scientific statement: recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke. 2001;32(6):1458–71. doi: 10.1161/01.STR.32.6.1458.
    1. Berman MF, Sciacca RR, Pile-Spellman J, Stapf C, Connolly ES, Jr, Mohr JP, et al. The epidemiology of brain arteriovenous malformations. Neurosurgery. 2000;47:389–96. doi: 10.1097/00006123-200008000-00023.
    1. Brown RD, Jr, Wiebers DO, Forbes G, O’Fallon WM, Piepgras DG, Marsh WR, et al. The natural history of unruptured intracranial arteriovenous malformations. J Neurosurg. 1988;68:352–7. doi: 10.3171/jns.1988.68.3.0352.
    1. Stapf C, Mohr JP, Pile-Spellman J, Solomon RA, Sacco RL, Connolly ES., Jr Epidemiology and natural history of arteriovenous malformations. Neurosurg Focus. 2001;11:e1. doi: 10.3171/foc.2001.11.5.2.
    1. Bendok BR, El Tecle NE, El Ahmadieh TY, Koht A, Gallagher TA, Carroll TJ, et al. Advances and innovations in brain arteriovenous malformation surgery. Neurosurgery. 2014;74(Suppl 1):S60–73. doi: 10.1227/NEU.0000000000000230.
    1. Davies JM, Yanamadala V, Lawton MT. Comparative effectiveness of treatments for cerebral arteriovenous malformations: trends in nationwide outcomes from 2000 to 2009. Neurosurg Focus. 2012;33:E11. doi: 10.3171/2012.5.FOCUS12107.
    1. Hartmann A, Mast H, Mohr JP, Pile-Spellman J, Connolly ES, Sciacca RR, et al. Determinants of staged endovascular and surgical treatment outcome of brain arteriovenous malformations. Stroke. 2005;36:2431–5. doi: 10.1161/01.STR.0000185723.98111.75.
    1. Hartmann A, Stapf C, Hofmeister C, Mohr JP, Sciacca RR, Stein BM, et al. Determinants of neurological outcome after surgery for brain arteriovenous malformation. Stroke. 2000;31:2361–4. doi: 10.1161/01.STR.31.10.2361.
    1. Plasencia AR, Santillan A. Embolization and radiosurgery for arteriovenous malformations. Surg Neurol Int. 2012;3:S90–104. doi: 10.4103/2152-7806.95420.
    1. Ross J, Al-Shahi SR. Interventions for treating brain arteriovenous malformations in adults. Cochrane Database Syst Rev. 2010;7:CD003436.
    1. Rubin BA, Brunswick A, Riina H, Kondziolka D. Advances in radiosurgery for arteriovenous malformations of the brain. Neurosurgery. 2014;74:S50–9. doi: 10.1227/NEU.0000000000000219.
    1. van Beijnum J, van der Worp HB, Buis DR, Al-Shahi Salman R, Kappelle LJ, Rinkel GJ, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306:2011–9. doi: 10.1001/jama.2011.1632.
    1. Cockroft KM, Chang KE, Lehman EB, Harbaugh RE. AVM Management Equipoise Survey: physician opinions regarding the management of brain arteriovenous malformations. J Neurointerv Surg. 2014;6:748–53. doi: 10.1136/neurintsurg-2013-011030.
    1. Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery. 2010;66:702–13. doi: 10.1227/01.NEU.0000367555.16733.E1.
    1. Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65:476–83. doi: 10.3171/jns.1986.65.4.0476.
    1. Starke RM, Komotar RJ, Hwang BY, Fischer LE, Garrett MC, Otten ML, et al. Treatment guidelines for cerebral arteriovenous malformation microsurgery. Br J Neurosurg. 2009;23:376–86. doi: 10.1080/02688690902977662.
    1. Mounayer C, Hammami N, Piotin M, Spelle L, Benndorf G, Kessler I, et al. Nidal embolization of brain arteriovenous malformations using Onyx in 94 patients. AJNR Am J Neuroradiol. 2007;28:518–23.
    1. Pierot L, Cognard C, Herbreteau D, Fransen H, van Rooij WJ, Boccardi E, et al. Endovascular treatment of brain arteriovenous malformations using a liquid embolic agent: results of a prospective, multicentre study (BRAVO) Eur Radiol. 2013;23:2838–45. doi: 10.1007/s00330-013-2870-6.
    1. Saatci I, Geyik S, Yavuz K, Cekirge HS. Endovascular treatment of brain arteriovenous malformations with prolonged intranidal Onyx injection technique: long-term results in 350 consecutive patients with completed endovascular treatment course. J Neurosurg. 2011;115:78–88. doi: 10.3171/2011.2.JNS09830.
    1. Andrade-Souza YM, Ramani M, Beachey DJ, Scora D, Tsao MN, Terbrugge K, et al. Liquid embolisation material reduces the delivered radiation dose: a physical experiment. Acta Neurochir (Wien) 2008;150:161–4. doi: 10.1007/s00701-007-1482-9.
    1. Andrade-Souza YM, Ramani M, Scora D, Tsao MN, ter Brugge K, Schwartz ML. Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations. Neurosurgery. 2007;60:443–51. doi: 10.1227/01.NEU.0000255347.25959.D0.
    1. Bing F, Doucet R, Lacroix F, Bahary JP, Darsaut T, Roy D, et al. Liquid embolization material reduces the delivered radiation dose: clinical myth or reality? AJNR Am J Neuroradiol. 2012;33:320–2. doi: 10.3174/ajnr.A2943.
    1. Morgan MK, Davidson AS, Koustais S, Simons M, Ritson EA. The failure of preoperative ethylene-vinyl alcohol copolymer embolization to improve outcomes in arteriovenous malformation management: case series. J Neurosurg. 2013;118:969–77. doi: 10.3171/2012.11.JNS112064.
    1. Raymond J, Naggara O, Guilbert F, Altman DG. Assessing prognosis from nonrandomized studies: an example from brain arteriovenous malformations. AJNR Am J Neuroradiol. 2011;32:809–12. doi: 10.3174/ajnr.A2516.
    1. da Costa L, Wallace MC, Ter Brugge KG, O’Kelly C, Willinsky RA, Tymianski M. The natural history and predictive features of hemorrhage from brain arteriovenous malformations. Stroke. 2009;40:100–5. doi: 10.1161/STROKEAHA.108.524678.
    1. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg. 2013;118:437–43. doi: 10.3171/2012.10.JNS121280.
    1. Hartmann A, Mast H, Mohr JP, Koennecke HC, Osipov A, Pile-Spellman J, et al. Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation. Stroke. 1998;29:931–4. doi: 10.1161/01.STR.29.5.931.
    1. Hernesniemi JA, Dashti R, Juvela S, Vaart K, Niemela M, Laakso A. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery. 2008;63:823–9. doi: 10.1227/01.NEU.0000330401.82582.5E.
    1. Wedderburn CJ, van Beijnum J, Bhattacharya JJ, Counsell CE, Papanastassiou V, Ritchie V, et al. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol. 2008;7:223–30. doi: 10.1016/S1474-4422(08)70026-7.
    1. Wilkins RH. Natural history of intracranial vascular malformations: a review. Neurosurgery. 1985;16:421–30. doi: 10.1227/00006123-198503000-00026.
    1. Stapf C, Mast H, Sciacca RR, Choi JH, Khaw AV, Connolly ES, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology. 2006;66:1350–5. doi: 10.1212/01.wnl.0000210524.68507.87.
    1. Starke RM, Komotar RJ, Hwang BY, Fischer LE, Otten ML, Merkow MB, et al. A comprehensive review of radiosurgery for cerebral arteriovenous malformations: outcomes, predictive factors, and grading scales. Stereotact Funct Neurosurg. 2008;86:191–9. doi: 10.1159/000126945.
    1. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383:614–21. doi: 10.1016/S0140-6736(13)62302-8.
    1. Magro E, Gentric JC, Darsaut TE, Ziegler D, Bojanowski MW, Raymond J. Responses to ARUBA: a systematic review and analysis for the design of future AVM trials. J Neurosurg. 2015; in press.
    1. Pierot L, Fiehler J, Cognard C, Soderman M, Spelle L. Will a randomized trial of unruptured brain arteriovenous malformations change our clinical practice? AJNR Am J Neuroradiol. 2014;35:416–7. doi: 10.3174/ajnr.A3867.
    1. Proust F, Roche PH, Meling TR. Does ARUBA study improve our knowledge as regards the management of unruptured brain arteriovenous malformations? Neurochirurgie. 2014;60:2–4. doi: 10.1016/j.neuchi.2014.01.001.
    1. Russin J, Spetzler R. Commentary: the ARUBA trial. Neurosurgery. 2014;75:E96–7. doi: 10.1227/NEU.0000000000000357.
    1. Stapf C, Mohr JP, Choi JH, Hartmann A, Mast H. Invasive treatment of unruptured brain arteriovenous malformations is experimental therapy. Curr Opin Neurol. 2006;19:63–8. doi: 10.1097/01.wco.0000200546.14668.78.
    1. Al-Shahi Salman R, White PM, Counsell CE, du Plessis J, van Beijnum J, Josephson CB, et al. Outcome after conservative management or intervention for unruptured brain arteriovenous malformations. JAMA. 2014;311:1661–9. doi: 10.1001/jama.2014.3200.
    1. Raymond J, Darsaut TE, Altman DG. Pragmatic trials can be designed as optimal medical care: principles and methods of care trials. J Clin Epidemiol. 2014;67:1150–6. doi: 10.1016/j.jclinepi.2014.04.010.
    1. Xu F, Zhong J, Ray A, Manjila S, Bambakidis NC. Stereotactic radiosurgery with and without embolization for intracranial arteriovenous malformations: a systematic review and meta-analysis. Neurosurg Focus. 2014;37:E16. doi: 10.3171/2014.6.FOCUS14178.
    1. Bruno A, Shah N, Lin C, Close B, Hess DC, Davis K, et al. Improving modified Rankin Scale assessment with a simplified questionnaire. Stroke. 2010;41:1048–50. doi: 10.1161/STROKEAHA.109.571562.
    1. Adamson J, Cockayne S, Puffer S, Torgerson DJ. Review of randomised trials using the post-randomised consent (Zelen’s) design. Contemp Clin Trials. 2006;27:305–19. doi: 10.1016/j.cct.2005.11.003.
    1. Zelen M. Randomized consent designs for clinical trials: an update. Stat Med. 1990;9:645–56. doi: 10.1002/sim.4780090611.
    1. Raymond J, Darsaut TE, Molyneux AJ. A trial on unruptured intracranial aneurysms (the TEAM trial): results, lessons from a failure and the necessity for clinical care trials. Trials. 2011;12:64. doi: 10.1186/1745-6215-12-64.
    1. Korja M, Hernesniemi J, Lawton MT, Spetzler RF, Morgan MK. Is cerebrovascular neurosurgery sacrificed on the altar of RCTs? Lancet. 2014;384:27–8. doi: 10.1016/S0140-6736(14)61109-0.
    1. Mocco J, O’Kelly C, Arthur A, Meyers PM, Hirsch JA, Woo HH, et al. Randomized clinical trials: the double edged sword. J Neurointerv Surg. 2013;5:387–90. doi: 10.1136/neurintsurg-2013-010882.
    1. Darsaut TE, Raymond J. Clinical trials: what are we afraid of, what should we do? J Neurointerv Surg. 24 Jan 2014. doi:10.1136/neurintsurg-2013-010970. [Epub ahead of print].

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner